Arrowhead to Present at RBC Capital Markets' Global Healthcare Conference
2014 RBC Capital Markets' Global Healthcare Conference
PASADENA, Calif. -- February 20, 2014
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that President and CEO,
Christopher Anzalone, Ph.D., will present at the 2014 RBC Capital Markets'
Global Healthcare Conference on Wednesday, February 26, 2014 at 3:30 p.m. EST
at the New York Palace Hotel.
A live webcast of the presentation can be accessed by visiting the News &
Events section of the company’s website,
http://www.arrowheadresearch.com/presentations. A replay will also be archived
on the website and available for 90 days.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to firstname.lastname@example.org.
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Press spacebar to pause and continue. Press esc to stop.